NHI.no
Annonse
Informasjon

Kronisk leverbetennelse

Kronisk leverbetennelse kan skyldes en rekke underliggende sykdommer, men infeksjon med hepatitt B og C dominerer. Tilstanden kan utvikle seg til skrumplever, leversvikt og leverkreft.

Årsakene til kronisk leverbetennelse er mange, selv om hepatitt B og C dominerer.

Sist oppdatert:

27. juni 2023

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Hepatitt C . Referanselisten for dette dokumentet vises nedenfor

  1. Folkehelseinstituttet. Hepatitt C - veileder for helsepersonell. Sist oppdatert 09.06.2023 fhi.no
  2. Den norske legeforening. Faglig veileder for utredning og behandling av hepatitt C hos voksne. 9. utgave, 2022. www.legeforeningen.no
  3. Smith DG, Bukh J, Kuiken C. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318. pmid:24115039 PubMed
  4. Statusrapport om eliminasjon av hepatitt B og C som folkehelseproblem i Norge Statusreport on the elimination of hepatitis B and C as a public health threat in Norway. Oslo:Folkehelseinstituttet, 2023.
  5. Personlig meddelelse, Robert Whitakker, FHI.
  6. Helsedirektoratet. Hepatitt C. Nasjonale faglige råd. Publisert april 2019. www.helsedirektoratet.no
  7. WHO. Hepatitis C. Last updated 27 July 2020. www.who.int
  8. Moradpour D, Penin F. Hepatitis C proteins: from structure to function. Curr Top Microbiol Immunol 2013; 369: 113. pmid:23463199 PubMed
  9. Horner SM, Gale M. Intracellular Innate Immune Cascades and Interferon Defenses That Control Hepatitis C Virus. J Interferon Cytokine Res 2009; 9: 489. pmid:2956657 PubMed
  10. Grebely J, Page K, Saks-Davis R. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014; 69: 109. pmid:23908124 PubMed
  11. Bartlett SR, Yu A, Chapinal N et al. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals. Liver Int. 2019 Dec;39(12):2261-2272. Epub 2019 Sep 20. PMID: 3144484 PubMed
  12. Armstrong GL, Alter MJ, McQuillan GM. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 3: 777. pmid:10706572 PubMed
  13. Thomas DL, Thio CL, Martin MP. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.. Nature 2009; 461: 798. pmid:19759533 PubMed
  14. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. Survival of hepatitis C virus in syringes: implcation for transmission among injection drug users. J Infect Dis 2010; 202: 984-90. PubMed
  15. Terrault NA, Dodge JL, Murphy EL. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 2013; 57: 881. pmid:23175457 PubMed
  16. Witt MD, Saeberg EC, Darilay A. Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011. Clin Infect Dis 2013; 57: 77. pmid:23532480 PubMed
  17. Nijmeijer BM, Koopsen J, Schinkel J et al. Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men. J Int AIDS Soc. 2019 Aug;22 Suppl 6(Suppl Suppl 6):e25348. PMID: 31468692 PubMed
  18. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300. PubMed
  19. Dalgard O, Konopski Z, Bosse FJ, et. al. Hepatitt C - utredning og behandling. Tidsskr Nor Legeforen 2011; 131: E1-8. Tidsskrift for Den norske legeforening
  20. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–S68. PMID: 25443346 PubMed
  21. Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018. pmid:29655836 PubMed
  22. Vanhommerig JW, Thomas XV, van der Meer JTM, et al. Hepatitis C virus (HCV) antibody dynamics following acute HCV infection and reinfection among HIV-infected men who have sex with men. Clin Infect Dis 2014; 59:1678. doi:10.1093/cid/ciu695
  23. Indolfi G, Resti M. Perinatal transmission og hepatitis C virus infection. JMed Virol 2009; 81: 836-43. PubMed
  24. Pembrey L, Newell ML, Tovo PA et al. The management of HCV infected pregnant women and their children European paediatric HCV network. J Hepatol 2005; 43: 515-25. PubMed
  25. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019. pmid:30765123 PubMed
  26. Cacoub P, Saadoun D. Extrahepatic Manifestations of Chronic HCV Infection. N Engl J Med. 2021 Mar 18;384(11):1038-1052. PMID: 33730456.
  27. Pakpoor J, Noyce A, Goldacre R, et al. Viral hepatitis and Parkinson disease: A national record-linkage study. Neurology 2017. PMID: 28356465 PubMed
  28. Ogawa E, Chien N, Kam L, et al. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C. JAMA Intern Med 2022. pmid:36508196 PubMed
  29. Midgard H, Weir A, Palmateer N, et al. HCV epidemiology in high-risk groups and the risk of reinfection. J Hepatol. 2016;65(1 Suppl):S33–S45. PMID: 27641987 PubMed
Annonse
Annonse